Guys This one is so Nasty , that no one can understand easy where the hack this scrip is moving , unless you have professional software and you use customized time frame and understand the direction and filter out noise
this one is an example , we made exit thinking it will further range up and then crack near 650 form our Longs , then we found out this one...
BUY CIPLA 462.25 TARGET 467-472.3-478 STOPLOSS 460.85
find view usefull - kindly post your comment - click like button - follow and enjoy benefits
all my views on intraday basis - Views given with clear entry target and very small stoploss
Cipla not able to maintain above the resistance zone of 480/490.
on 29.11, 4 hours candle , doji is follwed by a bearish candle
If support at 463 breaks, then reaching 445/450 is a high possibility
Cipla may move to the given target levels. Weekly Indicators are moving slowly from bearish to bullish side. Risk traders can buy at this level. Safe trader can enter above 490 on closing basis.
Vijayaraghavan,
Chennai
we can see there is loss of momentum in cipla and rsi is giving bearish divergence. cmp is 468. once it closes below 460, it can go downtill 440 which is also the neckline of the double top chart formation and central pivot point of this month. below 440 it can further go down till 400-410.
Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
CIPLA
